Spots Global Cancer Trial Database for Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases

Official Title: Adjuvant Chemotherapy With Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases- Randomized Phase III Study

Study ID: NCT00156975

Conditions

Colorectal Neoplasms

Liver Metastases

Interventions

Capecitabine

Oxaliplatin

Study Description

Brief Summary: Primary endpoint of the study is to prove the superiority of an adjuvant therapy with oxaliplatin/ capecitabine until the first occurrence of appearance of a tumour. Occurrences in the meaning of this study are the appearance of a relapse of the tumour, of metastases, of a second tumour or death of any reason.

Detailed Description: Prospective, randomized, multi-centre, open phase III study with two parallel groups of patients according to the eligibility criteria. The times in both hierarchical classified endpoints will be measured as times from randomization. Patients with macroscopic complete resection of colorectal liver metastases will be randomized in: Arm A: post-operative adjuvant therapy with Capecitabine/ Oxaliplatin over 6 months and follow-up or Arm B: follow-up Randomization: stratification after Scores of Fong et al: * number of metastases (1 vs. \>=1) * maximal diameter of the metastasis (\<= 5cm vs. \> 5cm) * disease free interval (\>= 12 months vs. \> 12 months) * CEA (\<= 200ng/l vs. \>200 ng/l) in the strata 0-1, 2 and \>= 3,